Claims for Patent: 8,202,513

Summary for Patent: 8,202,513

Title:	Aryl potassium channel blockers and uses thereof
Abstract:	The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
Inventor(s):	Flynn; Bernard Luke (Vermont, AU), Baell; Jonathan Bayldon (Ivanhoe, AU), Chaplin; Jason Hugh (DoubleView, AU), Gill; Gurmit Singh (Craigieburn, AU), Grobelny; Damian Wojciech (Watsonia, AU), Harvey; Andrew John (Goodwood, AU), Mould; Jorgen Alvar (Semaphore, AU), Paul; Dharam (Torrensville, AU)
Assignee:	Bionomics Limited (Thebarton, South Australia, AU)
Application Number:	12/681,763
Patent Claims:	1. A compound of formula (I) or a salt thereof: ##STR00130## wherein R.sub.1 is independently selected from hydrogen, cyano, halo, nitro, optionally substituted lower alkyl, optionally substituted aryl, --OR, --C(O)R, --C(O)OR, --OC(O)R (where R is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl), --C(O)NR'R'', --NR'C(O)R'' and --NR'R'' (where R' and R'' are independently selected from hydrogen or lower alkyl); R.sub.2 is --OR; R.sub.6 is selected from cyano, halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted C.sub.4-7 cycloalkenyl, --OR, --SR, --C(O)R, --C(O)OR, --OC(O)R (where R is selected from hydrogen, optionally substituted lower alkyl, lower alkenyl, lower alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl), --C(O)NR'R'', --NR'C(O)R'' and --NR'R'' (where R' and R'' are independently selected from hydrogen or lower alkyl); L is a divalent linker group of 2-6 atoms in length selected from optionally substituted C.sub.2-6 alkylene, optionally substituted C.sub.2-6 alkenylene, or optionally substituted C.sub.2-6 alkynylene; L' is (i) a divalent linker group of 2-6 atoms in length selected from optionally substituted C.sub.2-6 alkylene, optionally substituted C.sub.2-6 alkenylene, or optionally substituted C.sub.2-6 alkynylene; or (ii) --CH.sub.2--; Y is --O--; Y' is --O--; R.sub.5 is selected from optionally substituted alkyl, --OR, --C(O)R, --C(O)OR, SR, (where R is selected from optionally substituted C.sub.2-7 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl), --C(O)NR'R'', --NR'C(O)R'' and --NR'R'' (where R' and R'' are independently selected from hydrogen or lower alkyl); R.sub.4 is selected from substituted aryl, substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, optionally substituted heterocyclyloxy or --NR'''R'''' (where R''' is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl, and where R'''' is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl); and R.sub.7 is selected from optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, optionally substituted heterocyclyloxy or --NHR''' (where R''' is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl). 2. A compound according to claim 1 or a salt thereof wherein R.sub.1 is independently selected from cyano, halo, nitro, optionally substituted lower alkyl, optionally substituted aryl, --OR, --C(O)R, --C(O)OR, --OC(O)R (where R is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted aryl), --C(O)NR'R'', --NR'C(O)R'' and --NR'R'' (where R' and R'' are independently selected from hydrogen or lower alkyl). 3. A compound according to claim 1 or a salt thereof wherein R.sub.1 is independently selected from hydrogen, cyano, halo, optionally substituted lower alkyl, --O-optionally substituted lower alkyl, --C(O)-optionally substituted lower alkyl, and --C(O)NR'R'' (wherein R' and R'' are independently selected from hydrogen or lower alkyl). 4. A compound according to claim 1 or a salt thereof wherein R.sub.6 is selected from cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroaryl, optionally substituted C.sub.3-7 cycloalkyl, --O-optionally substituted lower alkyl, --O-optionally substituted C.sub.3-7 cycloalkyl, or --O-optionally substituted heteroaryl. 5. A compound according to claim 4 or a salt thereof wherein R.sub.6 is selected from halo, optionally substituted alkyl, or --O-optionally substituted lower alkyl. 6. A compound according to claim 1 or a salt thereof wherein L is a divalent linker group of 2-6 atoms in length selected from C.sub.2-6 alkylene, C.sub.2-6 alkenylene, or C.sub.2-6 alkynylene, each of which may be optionally substituted by a lower alkyl group. 7. A compound according to claim 1 or a salt thereof wherein L' is a divalent linker group of 1-6 atoms in length selected from C.sub.1-6 alkylene, C.sub.2-6 alkenylene, or C.sub.2-6 alkynylene. 8. A compound according to claim 1 or a salt thereof wherein R.sub.7 is selected from optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, or optionally substituted heterocyclyloxy. 9. A compound according to claim 8 or a salt thereof wherein R.sub.7 is optionally substituted aryl. 10. A compound according to claim 1 or a salt thereof wherein R.sub.4 is selected from optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, optionally substituted heterocyclyloxy, or --NHC.sub.3-7 cycloalkyl. 11. A compound according to claim 10 or a salt thereof wherein R.sub.4 is selected from optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, or --NHC.sub.3-7 cycloalkyl. 12. A compound according to claim 1 or a salt thereof wherein R.sub.4 is selected from azetidinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyrrolinyl (including 2 and 3 pyrrolinyls), dioxolane, furyl, thienyl, pyrrolyl, H-pyrrolyl, oxazolyl, oxadiazolyl, (including 1,2,3 and 1,2,4 oxadiazolyls) thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl (including 1,2,3 and 1,3,4 triazolyls), tetrazolyl, and thiadiazolyl (including 1,2,3 and 1,3,4 thiadiazolyls), pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyranyl (including 2H and 4H pyranyls), piperidinyl, morpholinyl, piperazinyl, 1,3,5-trithianyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, 1,4-dithianyl, and 1,4-dioxanyl; all of which may be optionally substituted with one or more groups selected from halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl (in particular --CF.sub.3), C.sub.1-6 haloalkoxy (such as --OCF.sub.3), --OH, phenyl, benzyl, phenoxy, benzyloxy, benzoyl, --NH.sub.2, --NHC.sub.1-4 alkyl, --N(C.sub.1-4 alkyl).sub.2, --CN, --NO.sub.2, mercapto, C.sub.1-6 alkylcarbonyl, C.sub.1-6alkoxycarbonyl and CO.sub.2H. 13. A compound according to claim 1 or a salt thereof wherein L is an optionally substituted propylene or butylene. 14. A compound according to claim 13 or a salt thereof wherein L is --CH.sub.2--CH.sub.2--CH(CH.sub.3)--, --CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--, or --CH.sub.2--CH.sub.2--CH.sub.2--. 15. A compound according to claim 1 or a salt thereof wherein R.sub.5 is methyl. 16. A compound according to claim 1 or a salt thereof wherein R.sub.6 is C.sub.1-3 alkyl. 17. A compound according to claim 16 or a salt thereof wherein R.sub.6 is methyl. 18. A compound selected from the group consisting of: 1-(3-Chloro-5-(3-(4-fluorophenyl)propoxy)-4-methoxy-2-methyl-6-(2-morphol- inoethoxy)phenyl)ethanone; 1-(3-Chloro-6-(cyclopentylamino)ethoxy)-5-(3-(4-fluorophenyl)propoxy-4-me- thoxy-2-methylphenyl)ethanone; 1-[3-[3-(4-Fluoro-phenyl)-propoxy]-4-methoxy-5,6-dimethyl-2-(2-morpholin-- 4-yl-ethoxy)-phenyl]-ethanone; 1-[3-[3-(4-Fluoro-phenyl)-butoxy]-4-methoxy-5,6-dimethyl-2-(2-pyridin-2-y- l-ethoxy)-phenyl]-ethanone; 1-[3-[3-(4-Fluoro-phenyl)-butoxy]-4-methoxy-5,6-dimethyl-2-(2-morpholin-4- -yl-ethoxy)-phenyl]-ethanone; 1-{2-(2-Cyclopentylamino-ethoxy)-3-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy- -5,6-dimethyl-phenyl}-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-(2-pyridi- n-2-yl-ethoxy)-phenyl]-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-(2-morpho- lin-4-yl-ethoxy)-phenyl]-ethanone; 1-[3-Chloro-6-(2-cyclopentylamino-ethoxy)-5-[3-(4-fluoro-phenyl)-butoxy]-- 4-methoxy-2-methyl-phenyl]-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-(2-piperi- din-1-yl-ethoxy)-phenyl]-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-6-[2-(4-fluoro-piperidin-1-yl)- -ethoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-6-[2-(R-3-fluoro-pyrrolidin-1-- yl)-ethoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-(pyridin-- 2-ylmethoxy)-phenyl]-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-6-[2-(4-hydroxy-piperidin-1-yl- )-ethoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-6-[2-(4-oxo-piperidin-1-yl)-et- hoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-6-[2-(4,4-difluoro-piperidin-1-yl)-ethoxy]-5-[3-(4-fluoro-phe- nyl)-butoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-6-[2-(3,3-difluoro-piperidin-1-yl)-ethoxy]-5-[3-(4-fluoro-phe- nyl)-butoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-[2-(pyraz- in-2-yloxy)-ethoxy]-phenyl}-ethanone; 1-{3-Chloro-5-[3-(4-fluorophenyl)-butoxy]-4-methoxy-2-methyl-6-(2-[1,2,4]- triazol-1-yl-ethoxy)-phenyl}-ethanone; 1-{3-Chloro-6-[2-(3,3-difluoro-azetidin-1-yl)-ethoxy]-5-[3-(4-fluoro-phen- yl)-butoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-(3-morpho- lin-4-yl-propoxy)-phenyl]-ethanone; 1-{3-Chloro-6-[3-(1,1-dioxo-thiomorpholin-4-yl)-propoxy]-5-[3-(4-fluoro-p- henyl)-butoxy]-4-methoxy-2-methyl-phenyl}-ethanone; 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-[3-(1-oxo- -thiomorpholin-4-yl)-propoxy]-phenyl}-ethanone; 1-(3-Chloro-4-methoxy-2-methyl-6-(2-morpholinoethoxy)-5-5 (4-phenyl butyl)phenyl)ethanone; 1-(3-Chloro-4-methoxy-2-methyl-5-(4-phenylbutyl)-6-(2-(pyridine-2-yl)etho- xy)phenyl)ethanone; 1-(3-Chloro-5-(4-(4-fluorophenyl)pentyl)-4-methoxy-2-methyl-6-(2-morpholi- no ethoxy)phenyl)ethanone; 1-[3-Chloro-5-[4-(4-fluoro-phenyl)-pentyl]-4-methoxy-2-methyl-6-(2-pyridi- n-2-yl-ethoxy)-phenyl]-ethanone; 1-[4-Methoxy-6-methyl-2-(2-morpholin-4-yl-ethoxy)-3-(3-phenyl-propoxy)-ph- enyl]-ethanone; 1-[3-Chloro-6-(2-cyclopentylamino-ethoxy)-4-methoxy-2-methyl-5-(3-phenyl-- propoxy)-phenyl]-ethanone; 1-[3-Chloro-6-[2-(3,3-difluoro-azetidin-1-yl)-ethoxy]-4-methoxy-2-methyl-- 5-(3-phenyl-propoxy)-phenyl]-ethanone; 1-[3-Chloro-4-methoxy-2-methyl-5-(3-phenyl-propoxy)-6-(2-thiomorpholin-4-- yl-ethoxy)-phenyl]-ethanone; 1-[3-Chloro-6-[2-(3,3-difluoro-pyrrolidin-1-yl)-ethoxy]-4-methoxy-2-methy- l-5-(3-phenyl-propoxy)-phenyl]-ethanone; 1-[3-Chloro-6-[2-(3-hydroxy-azetidin-1-yl)-ethoxy]-4-methoxy-2-methyl-5-(- 3-phenyl-propoxy)-phenyl]-ethanone; 1-{3-Chloro-6-[2-(3-oxo-azetidin-1-yl)-ethoxy]-4-methoxy-2-methyl-5-(3-ph- enyl-propoxy)-phenyl}-ethanone; 1-{3-Chloro-6-(2-dimethylamino-ethoxy)-5-[3-(4-fluoro-phenyl)-butoxy]-4-m- ethoxy-2-methyl-phenyl}-ethanone; 1-[3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-6-(2-imidazol-1-yl-ethoxy)-4-m- ethoxy-2-methyl-phenyl]-ethanone; and 1-{3-Chloro-5-[3-(4-fluoro-phenyl)-butoxy]-4-methoxy-2-methyl-6-[2-((S)-3- -methyl-morpholin-4-yl)-ethoxy]-phenyl}-ethanone, or a salt thereof. 19. A pharmaceutical composition comprising one or more compounds according to claim 1 or a salt thereof and optionally a pharmaceutically acceptable carrier or diluent. 20. A pharmaceutical composition according to claim 19 further comprising an additional immunosuppressive compound or other multiple sclerosis therapeutic. 21. A pharmaceutical composition according to claim 20 wherein the additional immunosuppressive compound or other multiple sclerosis therapeutic is selected from interferon beta-1b, interferon beta-1a, glatiramer acetate, natalizumab or mitoxantrone.

Details for Patent 8,202,513

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2027-10-04
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2027-10-04
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2027-10-04
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2027-10-04
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2027-10-04
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2027-10-04